{"id":18185,"date":"2025-12-16T09:00:00","date_gmt":"2025-12-16T09:00:00","guid":{"rendered":"https:\/\/www.gecp.pt\/?p=18185"},"modified":"2025-12-07T12:54:37","modified_gmt":"2025-12-07T12:54:37","slug":"ro2025-ana-rodrigues","status":"publish","type":"post","link":"https:\/\/www.gecp.pt\/en\/ro2025-ana-rodrigues\/","title":{"rendered":"Autumn Meeting &#8211; Interview with Dr. Ana Rodrigues"},"content":{"rendered":"<p><\/p>\n\n\n\n<p>Dr. Ana Rodrigues, oncologist and member of the Scientific Committee of the Lung Cancer Study Group (GECP), led the conference &#8220;New Drugs, New Toxicities,&#8221; highlighting the challenges of new therapies in the treatment of lung cancer.<\/p>\n\n\n\n<p>Regarding the main differences between conventional medications and new therapies, the specialist cited the &#8220;higher incidence of cutaneous effects that negatively affect the quality of life of patients with prolonged survival, making their management a challenge.&#8221;<\/p>\n\n\n\n<p>She also pointed to other relevant toxicities, such as &#8220;infusion toxicity, with many events in the first infusion, and a higher incidence of thromboembolic events.&#8221;<\/p>\n\n\n\n<p>Dr. Ana Rodrigues emphasized the importance of training healthcare professionals in the detection and management of these toxicities, reinforcing that &#8220;it is essential to invest in the continuing education of teams, as well as in the literacy of patients and society in general.&#8221;<\/p>\n\n\n\n<p><\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-18185\" data-postid=\"18185\" class=\"themify_builder_content themify_builder_content-18185 themify_builder tf_clear\">\n                    <div  data-lazy=\"1\" class=\"module_row themify_builder_row tb_z83m372 tb_first tf_w\">\n                        <div class=\"row_inner col_align_top tb_col_count_1 tf_box tf_rel\">\n                        <div  data-lazy=\"1\" class=\"module_column tb-column col-full tb_wiss372 first\">\n                    <!-- module video -->\n<div  class=\"module module-video tb_ng4k687 video-top\" data-lazy=\"1\">\n                    <div class=\"video-wrap-outer\">\n            <div class=\"video-wrap tf_rel tf_overflow\">\n                                    <noscript><iframe data-no-script src=\"https:\/\/www.youtube.com\/embed\/xuZFpCAojCM?pip=1&#038;playsinline=1\" allow=\"accelerometer;encrypted-media;gyroscope;picture-in-picture;fullscreen\" class=\"tf_abs tf_w tf_h\"><\/iframe><\/noscript>\n                                <\/div>\n            <!-- \/video-wrap -->\n        <\/div>\n        <!-- \/video-wrap-outer -->\n            <\/div>\n        <\/div>\n                        <\/div>\n        <\/div>\n        <\/div>\n<!--\/themify_builder_content-->\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>Dr. Ana Rodrigues, oncologist and member of the Scientific Committee of the Lung Cancer Study Group (GECP), led the conference &#8220;New Drugs, New Toxicities,&#8221; highlighting the challenges of new therapies in the treatment of lung cancer. Regarding the main differences&#8230;<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>","protected":false},"author":1,"featured_media":18130,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0},"categories":[183,118,189,160],"tags":[],"_links":{"self":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts\/18185"}],"collection":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/comments?post=18185"}],"version-history":[{"count":4,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts\/18185\/revisions"}],"predecessor-version":[{"id":18190,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts\/18185\/revisions\/18190"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/media\/18130"}],"wp:attachment":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/media?parent=18185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/categories?post=18185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/tags?post=18185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}